Connect Biopharma Announces Positive Preliminary Topline Data From Its Global Phase 2 Study Of Rademikibart As An Add-On Treatment For Acute Exacerbations In Adults With Copd And Type 2 Inflammation
Connect Biopharma Holdings Ltd NASDAQ:CNTB
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results.
Connect Biopharma announces positive preliminary Phase 2 topline data for rademikibart add-on in COPD
Connect Biopharma said its global Phase 2 study of rademikibart as an add-on treatment for acute exacerbations in adults with COPD and type 2 inflammation produced positive preliminary topline data.
CNTB - Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adult and Adolescent Participants with Asthma and Type 2 Inflammation
CNTB - Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adult and Adolescent Participants with Asthma and Type 2 Inflammation